Real-world data show weight loss after switching to the Wegovy pill, Lilly reports positive hand and foot atopic dermatitis data, and Teva wins FDA approval for a Xgeva biosimilar.
|Articles|March 15, 2002
- BioPharm International-03-15-2002
- Volume 15
- Issue 3
Outsourcing Outlook: Using Earned-Value Analysis for Better Project Management
Author(s)Jim Miller, Heather B. Hayes
by Heather B Hayes, a freelance writer, and Jim Miller, publisher of the Bio/Pharmaceutical Outsourcing Report EVA allows project managers to refer to tangible numbers, not just a gut feeling, in determining whether a project is advancing on time and within budget.
Advertisement
Articles in this issue
over 24 years ago
Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?over 24 years ago
Guest Editorial: Warning Letters ? A Symptom?over 24 years ago
The Importance of Freezing on Lyophilization Cycle Developmentover 24 years ago
Business Benefits of Computer Systems Validationover 24 years ago
A System Developer's Approach to ValidationAdvertisement
Related to this article
In the OCTANE real-world analysis presented at EASD 2026, adults who switched from injectable semaglutide or tirzepatide to once-daily oral semaglutide lost an average of 4.1% of body weight after 3 months.
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.
Sponsored
Meeta Gulyani, Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.
Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
Advertisement
Advertisement